0001169245-22-000081.txt : 20220610 0001169245-22-000081.hdr.sgml : 20220610 20220610162034 ACCESSION NUMBER: 0001169245-22-000081 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220519 FILED AS OF DATE: 20220610 DATE AS OF CHANGE: 20220610 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Humphries William D. CENTRAL INDEX KEY: 0001674278 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38697 FILM NUMBER: 221009167 MAIL ADDRESS: STREET 1: C/O STRATA SKIN SCIENCES, INC. STREET 2: 5 WALNUT GROVE DRIVE SUITE 140 CITY: HORSHAM STATE: PA ZIP: 19044 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PhaseBio Pharmaceuticals Inc CENTRAL INDEX KEY: 0001169245 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 030375697 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY STREET 2: SUITE 30 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: (610) 981-6500 MAIL ADDRESS: STREET 1: 1 GREAT VALLEY PARKWAY STREET 2: SUITE 30 CITY: MALVERN STATE: PA ZIP: 19355 FORMER COMPANY: FORMER CONFORMED NAME: Phase Biosciences Inc DATE OF NAME CHANGE: 20061013 FORMER COMPANY: FORMER CONFORMED NAME: DT BIOSCIENCES INC DATE OF NAME CHANGE: 20020315 4/A 1 wf-form4a_165489241494222.xml FORM 4/A X0306 4/A 2022-05-19 2022-05-20 0 0001169245 PhaseBio Pharmaceuticals Inc PHAS 0001674278 Humphries William D. C/O PHASEBIO PHARMACEUTICALS, INC. 1 GREAT VALLEY PARKWAY, SUITE 30 MALVERN PA 19355 1 0 0 0 Non-employee Director Stock Option (right to buy) 0.8419 2022-05-19 4 A 0 11842 0 A 2032-05-18 Common Stock 11842.0 11842 D Restricted Stock Units 2022-05-19 4 A 0 2538 0 A Common Stock 2538.0 2538 D This amendment is being filed to correct an error in the total Stock Options and RSUs acquired by the Reporting Person. All other information set forth in the May 20, 2022 Form 4 remains correct. The shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock. The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date. /s/ John P. Sharp, Attorney-in-fact 2022-06-10